GSK plans $30bn US investment as pharma faces tariff threat

(Sharecast News) - GSK has announced plans to invest $30bn across the US in research and development and supply chain infrastructure over the next five years, amid fears of tariffs being imposed on the pharma industry by US President Donald Trump, who is in the UK on a state visit. The company said it would commit $1.2bn towards advanced manufacturing facilities and AI and advanced digital technologies, to deliver new, next-generation biopharma factories and laboratories.

This includes building a new factory to make new medicines for respiratory disease and cancer with construction planned to start next year.

There will also be new AI and advanced digital technology capabilities across GSK's existing five manufacturing sites in Pennsylvania, North Carolina, Maryland, and Montana, new drug substance manufacturing capabilities and enhanced device and auto-injector capabilities and assembly, the pharma giant said on Wednesday.

Trump has threatened the sector with large tariffs as part of his global trade war - so far drugmakers have been spared extra levies.

Reporting by Frank Prenesti for Sharecast.com